prescription drug costs

Opinion: The Bad Politics of Carving-Out Medicaid Managed Care DrugsAbout half of states have transitioned at least some Medicaid beneficiaries away from fee-for-service (FFS) drug programs into drug plans integrated with managed care. Our policy analyst shares why he believes more should do so.
When given the chance, will patients choose cheaper prescription drugs?A new UC Berkeley study has surprising findings about reference pricing and patient drug selection.
Three reasons for nonadherenceUncover the root causes of why patients become nonadherent and be better positioned to improve the lives of patients and reduce costs through improved health outcomes.
Pharmacies Play a Key Role in One Business’ Mission to Help the Uninsured
Drug costs chief concern of Medicare recipientsMedicare Part D recipients are most concerned about prescription drug costs—and their co-pay costs are the most important factor when choosing a pharmacy.
Discussing drug cost with patients may be awkward, but it’s vital
Discussing drug cost with patients may be awkward, but it’s vitalWith the ever-growing armamentarium of new therapies available today, a conversation about prescription drug costs with patients is rapidly becoming a reality for every physician.
Top 3 challenges facing dermatologists
Top 3 challenges facing dermatologistsWe asked you what your key challenges have been this year. These are your top-of-mind concerns.
Do prescription drug monitoring programs work?
Do prescription drug monitoring programs work?An in-depth look at the effects of PDMPs, which are electronic databases used to track the prescribing and dispensing of controlled prescription drugs to patients.
Oncologists not prescribing expensive cancer drugsIn the latest controversy over the high cost of certain prescription medications, a recent Reuters article said that more oncologists won’t prescribe expensive drugs.
5 drugs headed for $1B or more in sales by 2020Global prescription drug sales should reach nearly $1 trillion by 2020, thanks in part to FDA approvals of breakthrough drugs for cancer, hepatitis C and other diseases, a new report finds.